Latest news

Thumbnail image for Vertex’ three-drug CF combo hits PhIII targets

Vertex’ three-drug CF combo hits PhIII targets

Vertex’ three-drug cystic fibrosis regimen - combining the investigational next-generation corrector VX-445 with Kalydeco (ivacaftor) and tezacaftor – has achieved primary endpoints of two Phase III studies in patients the condition.

7th March 2019

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download